ReviewBMJ global health2020
Targeting anticorruption interventions at the front line: developmental governance in health systems.
Review in BMJ global health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Health sector corruption and access to healthcare in Africa.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Measuring and assessing corruption in public health systems in low- and middle-income countries: a scoping review of methods.Health policy and planning · 2026Article
- How does the Nigerian health system serve people living with disabilities? A socio-ecological analysis on people living with visual impairment.Global health action · 2025Review
- Practical norms in emerging infectious disease control: lessons for transnational collaboration from a suspected newly emerging zoonosis outbreak in Ghana.BMJ global health · 2025Article
- The Future Hospital in Global Health Systems: The Future Hospital as an Entity.The International journal of health planning and management · 2025Review
- Who Is Most Likely to Experience Corruption When Seeking Healthcare in Nigerian Healthcare Facilities?International journal of health policy and management · 2025Article
- Deconcentrating regulation in low- and middle-income country health systems: a proposed ambidextrous solution to problems with professional regulation for doctors and nurses in Kenya and Uganda.Human resources for health · 2024Article
- Who is absent and why? Factors affecting doctor absenteeism in Bangladesh.PLOS global public health · 2024Article
- Examining corruption risks in the procurement and distribution of COVID-19 vaccines in select states in Nigeria.Journal of pharmaceutical policy and practice · 2023Article
- "I can't kill myself": Local narratives and meanings that foster absenteeism in Nigerian primary health centres.Journal of global health · 2023Article
- Lessons from Malawi's Farm Input Subsidy Programme.Nature food · 2023Article
- Article
- Is it possible for drug shops to abide by the formal rules? The structural determinants of community medicine sales in Uganda.BMJ global health · 2023Article
- Re-aligning Incentives to Address Informal Payments in Tanzania Public Health Facilities: A Discrete Choice Experiment.International journal of health policy and management · 2023Review
- Absenteeism in primary health centres in Nigeria: leveraging power, politics and kinship.BMJ global health · 2022Article
- The gendered drivers of absenteeism in the Nigerian health system.Health policy and planning · 2022Article
- Corruption should be taken into account when considering COVID-19 vaccine allocation.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Incentivising doctor attendance in rural Bangladesh: a latent class analysis of a discrete choice experiment.BMJ global health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2008, Vian reported an increasing interest in understanding how corruption affects healthcare outcomes and asked what could be done to combat corruption in the health sector. Eleven years later, corruption is seen as a heterogeneous mix of activity, extensive and expensive in terms of loss of productivity, increasing inequity and costs, but with few examples of programmes that have successfully tackled corruption in low-income or middle-income countries. The commitment, by multilateral organisations and many governments to the Sustainable Development Goals and Universal Health Coverage has renewed an interest to find ways to tackle corruption within health systems. These efforts must, however, begin with a critical assessment of the existing theoretical models and approaches that have underpinned action in the health sector in the past and an assessment of the potential of innovations from anticorruption work developed in sectors other than health. To that end, this paper maps the key debates and theoretical frameworks that have dominated research on corruption in health. It examines their limitations, the blind spots that they create in terms of the questions asked, and the capacity for research to take account of contextual factors that drive practice. It draws on new work from heterodox economics which seeks to target anticorruption interventions at practices that have high impact and which are politically and economically feasible to address. We consider how such approaches can be adopted into health systems and what new questions need to be addressed by researchers to support the development of sustainable solutions to corruption. We present a short case study from Bangladesh to show how such an approach reveals new perspectives on actors and drivers of corruption practice. We conclude by considering the most important areas for research and policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.